Medical disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Hormone management requires individual clinical assessment. Always consult a qualified healthcare practitioner before making changes to medications, supplements, or hormone therapy.

Estradiol (E2): Optimal Ranges for Women and Men Beyond the Lab Reference

Estradiol is simultaneously one of the most tested and most poorly interpreted hormones in clinical practice. Practitioners order it, patients receive a result with a printed reference range, and the conversation rarely goes further than "normal" or "low." The problem is that the conventional reference ranges are so wide — and so context-dependent — that a result sitting squarely within range can be functionally inadequate, while a result flagged as elevated may be entirely appropriate for the clinical picture.

Understanding estradiol properly means understanding synthesis, tissue specificity, cyclical variation, counter-regulatory hormones, and the difference between what a laboratory considers acceptable and what a functional medicine framework considers optimal. This article covers all of that, with particular attention to Australian reference ranges, the oestrogen:progesterone ratio, and the often-overlooked relevance of E2 in men.

What Is Estradiol?

Estradiol — technically oestradiol-17β (E2) — is the most potent and biologically active of the three endogenous oestrogens, alongside oestrone (E1) and oestriol (E3). In premenopausal women, the dominant source is the granulosa cells of ovarian follicles, where testosterone is converted to estradiol via the enzyme aromatase (CYP19A1). Smaller amounts are produced in the adrenal cortex, adipose tissue, liver, and brain.

In men, and in postmenopausal women, peripheral aromatisation becomes the primary source: adipose tissue, the liver, muscle, and — in men specifically — the Leydig cells of the testes all express aromatase and convert circulating testosterone and androstenedione to estradiol. This is why body composition, liver function, and DHEA-S as an adrenal androgen precursor all influence estradiol levels, independent of gonadal function.

Estradiol acts through two nuclear receptor subtypes: oestrogen receptor alpha (ERα) and oestrogen receptor beta (ERβ). These are expressed differently across tissues, and their relative balance determines the biological effect:

• ERα predominates in the uterus, breast, liver, and hypothalamus. It drives proliferative effects in reproductive tissues — which is why sustained, unopposed ERα stimulation is associated with endometrial and breast pathology.
• ERβ predominates in bone, the cardiovascular system, the brain, the ovaries, and the lungs. Its activation is broadly protective — anti-proliferative in breast tissue, vasodilatory in blood vessels, and neuroprotective in the central nervous system.

This receptor distribution explains why low estradiol affects cognition, mood, cardiovascular risk, and skeletal integrity — these are all ERβ-mediated effects operating in the background of everyday physiology, only becoming obvious when E2 declines.

Australian Conventional Reference Ranges

Australian pathology laboratories reference the ranges compiled by the Australasian Association of Clinical Biochemists and published through resources such as Pathology Tests Explained (ptex.au), which is linked from the Australian Government's My Health Record framework. For estradiol (serum, immunoassay), the conventional ranges are as follows:

Premenopausal women (cycle phase dependent):

• Follicular phase: 77–921 pmol/L
• Mid-cycle peak (LH surge): up to 1835 pmol/L
• Luteal phase: 77–1145 pmol/L

Postmenopausal women: <183 pmol/L

Men: 40–161 pmol/L

The first thing to notice about these ranges is their breadth. A follicular-phase estradiol of 80 pmol/L and one of 900 pmol/L are both reported as "normal," yet they represent physiological states that could not be more different. For a woman investigating unexplained fatigue, low libido, or poor sleep quality, knowing that her follicular-phase E2 is 85 pmol/L rather than 350 pmol/L is clinically meaningful — but standard reporting obscures this entirely.

The postmenopausal upper reference of <183 pmol/L is similarly unhelpful. It tells you what is common in that population, not what is optimal. A postmenopausal woman on no hormone therapy with an E2 of 40 pmol/L and one with an E2 of 160 pmol/L have very different bone resorption rates, cardiovascular profiles, and cognitive trajectories — yet both are "within range."

Functional Optimal Targets

Functional medicine and anti-ageing frameworks use tighter, context-specific targets that reflect the physiology of a well-functioning endocrine system rather than population averages:

Premenopausal women:

• Follicular phase: 200–400 pmol/L
• Luteal phase: 400–600 pmol/L
• Mid-cycle peak: 800–1200 pmol/L (consistent with a robust LH surge)

Women consistently falling below the lower end of these phase-specific targets — particularly with follicular E2 persistently below 150 pmol/L — are likely entering perimenopause or experiencing hypothalamic suppression from low body weight, over-training, or chronic stress.

Postmenopausal women on HRT: 200–400 pmol/L. This range is associated with maintained bone mineral density, preserved cognitive performance, and favourable cardiovascular lipid profiles in the published HRT literature. It is achievable with standard transdermal oestradiol preparations and should be monitored periodically to confirm absorption.

Men: 80–130 pmol/L. This is the functional sweet spot for male estradiol — high enough to protect bone density, support libido, and maintain cognitive function, but low enough to avoid the symptoms of oestrogen excess. Below 70 pmol/L in men, hip fracture risk increases, libido declines, and mood effects emerge. Above 160–180 pmol/L, aromatase excess begins to produce clinical consequences.

Low Oestrogen: The Perimenopausal Cascade

The perimenopausal transition typically begins in the mid-to-late 40s and is characterised by progressive follicular depletion and increasingly erratic ovarian oestrogen production. FSH rises (often above 10–15 IU/L), cycles shorten and then lengthen, and estradiol levels become unpredictable before declining overall.

The clinical consequences of falling estradiol extend well beyond hot flushes, though vasomotor symptoms — driven by oestrogen withdrawal effects on hypothalamic thermoregulation — are often the presenting complaint. The broader physiological cascade includes:

Bone density loss. Oestrogen is the primary brake on osteoclast activity. Once E2 falls below the functional threshold, osteoclasts — the cells that resorb bone — become more active without a proportional increase in osteoblastic formation. In the first one to three years of menopause, women can lose 2–3% of bone mineral density per year, a rate that significantly outpaces age-related loss in men or younger women. Over a decade, this translates to structural bone loss that substantially increases fracture risk.

Cognitive and mood effects. The hippocampus and prefrontal cortex are both rich in ERβ. Oestradiol promotes neurogenesis, supports serotonin and acetylcholine synthesis, and reduces amyloid-beta burden in animal models. The cognitive fog, word-finding difficulty, and mood instability common in perimenopause are consistent with ERβ withdrawal, and several longitudinal studies have found that verbal memory declines are steepest in the years immediately surrounding menopause.

Cardiovascular risk shift. Premenopausal women have substantially lower rates of cardiovascular disease than age-matched men — a protection that erodes after menopause. Oestrogen maintains favourable HDL/LDL ratios, supports endothelial nitric oxide production, reduces arterial stiffness, and has direct anti-inflammatory effects on vessel walls. Loss of this protection is a primary reason cardiovascular disease becomes the leading cause of death in women over 60.

Sleep disruption. Oestrogen supports the architecture of deep NREM sleep and modulates nocturnal temperature stability. Hot flushes compound this, fragmenting sleep at a time when the hormonal support for sleep quality is already compromised.

Oestrogen Dominance: Relative Excess and the Progesterone Problem

Elevated estradiol in women is less common than oestrogen dominance — a state where the ratio of oestrogen to progesterone is unfavourable, regardless of whether the absolute E2 level is elevated. This distinction matters enormously.

In the late reproductive years and early perimenopause, progesterone often falls faster than estradiol. Anovulatory cycles — common in the perimenopausal transition — produce no corpus luteum and therefore no progesterone surge. A woman can have a midluteal estradiol of 380 pmol/L and a progesterone of 3 nmol/L (a level reflecting failed or absent ovulation) and be described as "normal" by a lab result, while experiencing the full clinical picture of oestrogen dominance: breast tenderness and fibrocystic changes, heavy and irregular bleeding, endometrial proliferation, mood swings, water retention, and sleep disruption.

The functional target for the mid-luteal oestrogen:progesterone ratio is generally cited as approximately 1:200 to 1:300 when E2 is in pmol/L and progesterone is in nmol/L (or roughly 10:1 to 35:1 in the same unit systems used by some Dutch test platforms). What matters is that progesterone is sufficiently elevated to counter-regulate E2's proliferative effects on the uterus and breast. Unopposed oestrogen without adequate progesterone is the driver of endometrial hyperplasia and, over time, is associated with increased endometrial cancer risk.

True estradiol excess — absolute hyperoestrogenaemia — does occur and is most commonly seen in the context of aromatase overactivity in men with high adiposity, but can also reflect exogenous oestrogen use without appropriate monitoring, or, rarely, oestrogen-secreting tumours.

Estradiol in Men: The Overlooked Axis

Men maintain estradiol throughout life, and its roles in male physiology are significant and underappreciated. The 40–161 pmol/L conventional range captures most men, but the functional optimum is narrower: 80–130 pmol/L.

Why men need adequate E2. Bone mineral density in men is substantially dependent on estradiol — more so than testosterone alone. Studies of men with aromatase deficiency (a genetic inability to convert androgens to oestrogens) show severe osteoporosis and growth plate abnormalities, all of which respond to oestradiol replacement but not testosterone. Libido in men is similarly bidirectional: deficient either in testosterone or in estradiol, and sexual function declines. The brain, cardiovascular system, and joints all express ERβ in men, and low E2 in men is associated with cognitive effects that parallel those seen in oestrogen-deficient women.

Drivers of elevated E2 in men. Aromatase activity is upregulated by several modifiable factors:

• Adiposity. Adipose tissue is the largest peripheral aromatase site. Men with high body fat aromatise more testosterone to estradiol, often suppressing testicular LH-stimulated testosterone production through negative feedback and creating a cycle of low testosterone and high E2.
• Alcohol. Alcohol acutely increases aromatase activity and reduces hepatic clearance of oestrogens. Chronic alcohol use is a consistent cause of elevated E2 with secondary hypogonadism.
• Finasteride. This 5-alpha reductase inhibitor reduces DHT but shifts the androgenic substrate toward aromatisation, often raising E2. Men on finasteride for hair loss or BPH who develop symptoms of oestrogen excess should have E2 monitored.
• Low SHBG. Low sex hormone-binding globulin increases free oestradiol bioavailability. Since SHBG binds E2 with moderate affinity, men with metabolic syndrome and suppressed SHBG may have functionally elevated oestrogen activity even when total E2 appears within range.

Managing elevated E2 in men. Clinical approaches range from lifestyle-first (adiposity reduction, alcohol reduction) to targeted supplementation with diindolylmethane (DIM), which modulates oestrogen metabolism toward less potent metabolites via 2-hydroxylation. Anastrozole — an aromatase inhibitor — is used in supervised clinical contexts, particularly in men on testosterone replacement therapy where exogenous testosterone substantially increases aromatase substrate. It should not be used indiscriminately: suppressing E2 below 70 pmol/L in men causes bone loss, joint pain, mood disturbance, and libido decline. For those exploring structured hormone optimisation protocols, resources like RetaLABS research provide a useful overview of evidence-based approaches to managing the testosterone-oestrogen axis.

The relationship between testosterone, SHBG, and estradiol in men is intricate. A full picture always requires interpreting testosterone alongside SHBG and free androgen index rather than reading E2 in isolation.

Testing: Which Method, When, and Why It Matters

Serum estradiol (ECLIA immunoassay). This is the standard method used by Australian pathology laboratories — Medicare-rebatable and widely available. It measures total estradiol (protein-bound plus free). The limitation is that ECLIA immunoassays have known cross-reactivity issues, particularly at low concentrations (postmenopausal range), where they can over-read. Mass spectrometry (LC-MS/MS) is more accurate at low levels but not routinely available or rebated. For most clinical purposes, ECLIA is adequate, particularly in premenopausal women where E2 concentrations are high enough to be reliably measured.

Cycle timing is non-negotiable for premenopausal women. An E2 of 220 pmol/L means entirely different things on day 3 versus day 21 of a cycle. Baseline or "follicular-phase" testing should occur on days 2–4 of the cycle (day 1 = first day of menstrual bleeding). Midluteal testing (day 19–22 of a 28-day cycle) captures the oestrogen and progesterone peak and is necessary for assessing luteal adequacy and the oestrogen:progesterone ratio. Always note cycle day on any hormone requisition.

Dutch Complete test (dried urine). The Dutch test measures urinary oestrogen metabolites — oestradiol, oestrone, oestriol — as well as their downstream metabolites (2-OH, 4-OH, 16-OH oestrogens). This provides insight into oestrogen metabolism pathways that serum E2 cannot. The 2-hydroxylation pathway (producing 2-hydroxyoestrone) is generally considered protective, while 4-hydroxylation produces DNA-reactive intermediates of greater concern. For women with a history of hormone-sensitive cancers, oestrogen dominance symptoms, or those on HRT wanting metabolic monitoring, the Dutch test adds meaningful depth. It also measures cortisol, DHEA, and androgens, making it a comprehensive functional hormone map.

Saliva testing. Salivary estradiol measures free, unbound hormone. While theoretically attractive, salivary oestrogen testing has poor analytical reliability and wide interlaboratory variation. It is rarely recommended for clinical decision-making in Australia and is not Medicare-rebatable. Dutch urine testing is a better alternative when serum E2 is insufficient.

Putting It Together: Reading E2 in Context

Estradiol does not exist in a vacuum. It interacts with every major component of the hormonal milieu — progesterone, testosterone, SHBG, cortisol, and insulin. A meaningful hormonal assessment considers:

• E2 in the context of cycle phase (premenopausal women)
• The oestrogen:progesterone ratio in the mid-luteal phase
• SHBG, which modulates free E2 bioavailability — low SHBG amplifies both oestrogen and androgen activity
• Testosterone levels, since testosterone is the direct precursor to E2 via aromatase
• Body composition, liver function, and alcohol use as aromatase modifiers
• Adrenal androgen status via DHEA-S, particularly relevant in postmenopausal women whose residual oestrogen depends on peripheral DHEA-S conversion

For a full picture of the hormonal substrate, the SHBG, testosterone, and DHEA-S panels should ideally be run simultaneously with E2. Each marker illuminates a different part of the same system. The SHBG article on rawmarkers.com covers how SHBG modulates bioavailable sex hormones across both sexes — a critical layer when E2 results seem inconsistent with the clinical presentation.

Key Takeaways

Estradiol is a context-dependent marker. The conventional reference ranges provided by Australian pathology are population descriptors, not functional targets. For clinical interpretation, what matters is the cycle phase, the relationship with progesterone, the SHBG context, and whether the result makes physiological sense given the individual's symptoms, age, body composition, and hormonal history.

Low E2 in premenopausal women signals the perimenopausal transition or functional suppression and carries real consequences for bone, cardiovascular health, and cognition. In postmenopausal women, the optimal range on HRT is 200–400 pmol/L — well above the conventional upper limit — because that upper limit simply reflects what is common, not what is healthy. In men, both extremes carry risk: too low impairs bone density and libido; too high reflects aromatase excess, usually driven by modifiable factors.

The oestrogen:progesterone ratio is more clinically informative than E2 alone in most premenopausal and perimenopausal contexts. And in men, E2 should always be read alongside testosterone and SHBG as part of an integrated andrological picture.

Estradiol interpreted in isolation is a number. Estradiol interpreted in context is a clinical story.